Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 01 Jan 2023 Results assessing relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine de-novo indirect treatment comparisons (ITCs) based on results from NCT02066415, PREEMPT 1 & PREEMPT 2,published in the Current Medical Research and Opinion.
- 09 Nov 2022 Results of cost effectiveness analysis from NCT02066415, STRIVE, ARISE, LIBERTY and HER-MES presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 13 Oct 2022 Results of post-hoc analysis of 4 studies (NCT02456740, NCT02066415, NCT02630459, and NCT03812224) assessing consistency of erenumab effect throughout the monthly treatment cycle, published in the Headache.